Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM) from its SEC filings: 2025 revenue $139.7 million (+120% vs the year before), net margin -57%, free cash flow -$360.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $139.7 million |
| Revenue growth | +120% |
| Net income | -$80.0 million |
| Net margin | -57.2% |
| Free cash flow | -$360.0 million |
| Diluted EPS | $-0.81 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -94% |
| Cash | $219.8 million |
| Long-term debt | $100.3 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.